New United States patent granted for Patrys deoxymab assets

• A patent covering the use of Patrys’ novel deoxymabs (including both PAT-DX1 and PAT-DX3) in combination with radiosensitising agent(s) that damage DNA or inhibit DNA repair, such as cisplatin and doxorubicin, has been granted in the United States. • This new patent further expands Patrys’ patent estate which covers a range of different ways to use Patrys’ novel deoxymabs in their unconjugated f